AUB ScholarWorks

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study

Show simple item record Taher A. Elalfy M.S. Al Zir K. Daar S. Al Jefri A. Habr D. Kriemler-Krahn U. Roubert B. El-Beshlawy A.
dc.contributor.editor Oct-2011 2017-10-05T15:37:58Z 2017-10-05T15:37:58Z 2011
dc.identifier 10.1111/j.1600-0609.2011.01661.x
dc.identifier.issn 09024441
dc.description.abstract This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe-g dry weight (dw) at 2yr (P0.001) in patients with LIC ≥7mg Fe-g dw at baseline; patients with LIC 7mg Fe-g dw maintained these levels over the treatment period. The proportion of patients with LIC 7mg Fe-g dw increased from 9.4percent at core baseline to 39.3percent by the end of year 2. The results showed that deferasirox enabled therapeutic goals to be achieved, by maintaining LIC in patients with LIC 7mg Fe-g dw at a mean dose of 22.4±5.2mg-kg-d and significantly reducing LIC in patients with LIC ≥7mg Fe-g dw at a mean dose of 25.7±4.2mg-kg-d, along with a manageable safety profile. © 2011 John Wiley and Sons A-S.
dc.format.extent Pages: (349-354)
dc.language English
dc.publisher MALDEN
dc.relation.ispartof Publication Name: European Journal of Haematology; Publication Year: 2011; Volume: 87; no. 4; Pages: (349-354);
dc.source Scopus
dc.title Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study
dc.type Article
dc.contributor.affiliation Taher, A., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Elalfy, M.S., Ain Shams University, Cairo, Egypt
dc.contributor.affiliation Al Zir, K., National Thalassemia Center, Damascus, Syrian Arab Republic
dc.contributor.affiliation Daar, S., Sultan Qaboos University, Muscat, Oman
dc.contributor.affiliation Al Jefri, A., King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
dc.contributor.affiliation Habr, D., Novartis Pharmaceuticals, East Hanover, NJ, United States
dc.contributor.affiliation Kriemler-Krahn, U., Novartis Pharma AG, Basel, Switzerland
dc.contributor.affiliation Roubert, B., Novartis Pharma AG, Basel, Switzerland
dc.contributor.affiliation El-Beshlawy, A., Cairo University, Cairo, Egypt
dc.contributor.authorAddress Taher, A.; American University of Beirut Medical Center, PO Box: 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Taher, A
dc.contributor.authorInitials Elalfy, MS
dc.contributor.authorInitials Al Zir, K
dc.contributor.authorInitials Daar, S
dc.contributor.authorInitials Al Jefri, A
dc.contributor.authorInitials Habr, D
dc.contributor.authorInitials Kriemler-Krahn, U
dc.contributor.authorInitials Roubert, B
dc.contributor.authorInitials El-Beshlawy, A
dc.contributor.authorReprintAddress Taher, A (reprint author), Amer Univ Beirut, Med Ctr, POB 11-0236, Beirut 11072020, Lebanon.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056-NEJM199409013310903; Olivieri NF, 1997, BLOOD, V89, P739; PFISTERER ME, 1985, EUR HEART J, V6, P647; Porter JB, 2010, HAEMATOLOGICA S2, V95; Taher A, 2009, EUR J HAEMATOL, V82, P458, DOI 10.1111-j.1600-0609.2009.01228.x; TAHER A, EUR J HAEMA IN PRESS
dc.description.citedCount 1
dc.description.citedTotWOSCount 2
dc.description.citedWOSCount 2
dc.format.extentCount 6
dc.identifier.coden EJHAE
dc.identifier.pubmedID 21668501
dc.identifier.scopusID 80053284827
dc.publisher.address COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
dc.relation.ispartOfISOAbbr Eur. J. Haematol.
dc.relation.ispartOfIssue 4
dc.relation.ispartofPubTitle European Journal of Haematology
dc.relation.ispartofPubTitleAbbr Eur. J. Haematol.
dc.relation.ispartOfVolume 87
dc.source.ID WOS:000295223400007
dc.type.publication Journal
dc.subject.otherAuthKeyword β-thalassaemia
dc.subject.otherAuthKeyword Deferasirox
dc.subject.otherAuthKeyword Efficacy
dc.subject.otherAuthKeyword Iron chelation therapy
dc.subject.otherAuthKeyword Iron overload
dc.subject.otherChemCAS deferasirox, 201530-41-8
dc.subject.otherChemCAS deferiprone, 30652-11-0
dc.subject.otherChemCAS iron, 14093-02-8, 53858-86-9, 7439-89-6
dc.subject.otherChemCAS Benzoic Acids
dc.subject.otherChemCAS Iron, 7439-89-6
dc.subject.otherChemCAS Iron Chelating Agents
dc.subject.otherChemCAS Triazoles
dc.subject.otherChemCAS deferasirox
dc.subject.otherIndex deferasirox
dc.subject.otherIndex deferiprone
dc.subject.otherIndex iron
dc.subject.otherIndex abnormal laboratory result
dc.subject.otherIndex adolescent
dc.subject.otherIndex article
dc.subject.otherIndex beta thalassemia
dc.subject.otherIndex child
dc.subject.otherIndex creatinine blood level
dc.subject.otherIndex death
dc.subject.otherIndex dose response
dc.subject.otherIndex drug dose increase
dc.subject.otherIndex drug dose reduction
dc.subject.otherIndex drug effect
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug eruption
dc.subject.otherIndex drug safety
dc.subject.otherIndex female
dc.subject.otherIndex heart left ventricle ejection fraction
dc.subject.otherIndex human
dc.subject.otherIndex iron intake
dc.subject.otherIndex iron overload
dc.subject.otherIndex liver iron concentration
dc.subject.otherIndex liver level
dc.subject.otherIndex loading drug dose
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex multicenter study
dc.subject.otherIndex nausea and vomiting
dc.subject.otherIndex obstructive jaundice
dc.subject.otherIndex open study
dc.subject.otherIndex outcome assessment
dc.subject.otherIndex preschool child
dc.subject.otherIndex priority journal
dc.subject.otherIndex prospective study
dc.subject.otherIndex proteinuria
dc.subject.otherIndex school child
dc.subject.otherIndex side effect
dc.subject.otherIndex treatment duration
dc.subject.otherIndex treatment refusal
dc.subject.otherIndex treatment withdrawal
dc.subject.otherIndex ulcer perforation
dc.subject.otherIndex Adolescent
dc.subject.otherIndex Benzoic Acids
dc.subject.otherIndex beta-Thalassemia
dc.subject.otherIndex Body Burden
dc.subject.otherIndex Child
dc.subject.otherIndex Child, Preschool
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Iron
dc.subject.otherIndex Iron Chelating Agents
dc.subject.otherIndex Male
dc.subject.otherIndex Prospective Studies
dc.subject.otherIndex Triazoles
dc.subject.otherWOS Hematology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account